Epitan resumes sustained release trial

By Renate Krelle
Tuesday, 06 July, 2004

Melbourne-based EpiTan (ASX:EPT) has resumed its trial of the sustained release implant for tanning drug Melanotan.

The trial is being conducted at Queensland's Clive Berghofer Cancer Research Centre with a new significantly smaller solid injectable. It will be used to determine the optimal dose for the final commercial formulation of Melanotan.

Epitan executive chairman Dr Wayne Millen said the new implant was able to be injected with a 16 gauge needle.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd